Abstract
BackgroundChronic myeloid leukemia (CML) and acute myeloid leukemia (AML) are two common malignant disorders in leukemia. Although potent drugs are emerging, CML and AML may still relapse after the drug treatment is stopped. N6-methyladenosine (m6A) and lncRNAs play certain roles in the occurrence and development of tumors, but m6A-modified LncRNAs in ML remain to be further investigated.MethodsIn this study, we extracted and analyzed the TCGA gene expression profile of 151 ML patients and the clinical data. On this basis, we then evaluated the immune infiltration capacity of ML and LASSO-penalized Cox analysis was applied to construct the prognostic model based on m6A related lncRNAs to verify the prognostic risk in clinical features of ML. Quantitative reverse transcription PCR was used to detect the expression level of LncRNA in in ML cell lines K562, MOLM13 and acute monocytic leukemia cell line THP-1.ResultsWe found 70 m6A-related lncRNAs that were related to prognosis, and speculated that the content of stromal cells and immune cells would correlate with the survival of patients with ML. Next, Prognostic risk model of m6A-related lncRNAs was validated to have excellent consistency in clinical features of ML. Finally, we verified the expression levels of CRNDE, CHROMR and NARF-IT1 in ML cell lines K562, MOLM13 and acute monocytic leukemia cell line THP-1, which were significant.ConclusionsThe research provides clues for the prognosis prediction of ML patients by using the m6A-related lncRNAs model we have created, and clarifies the accuracy and authenticity of it.
Highlights
Chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) are two common malignant disorders in leukemia
We analyzed m6A-related lncRNAs related to survival with survival R package, samples were screened according to p-value < 0.01
Identification and consensus clustering analysis of m6A‐related lncRNAs in patients with ML The expression data of 14,086 lncRNAs and 23 m6A genes were obtained from the TCGA database and analyzed
Summary
Chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) are two common malignant disorders in leukemia. Chronic myeloid leukemia (CML) and acute myeloid leukemia(AML) are two common malignant disorders in leukemia [1]. They have different forms and different age distributions, AML mostly occur in older adults, the significance is increasing in patients aged ≥ 60 years and the incidence is higher in males than in females [2]. LncRNAs are involved in almost all the disease processes, such as diabetes, heart diseases, and different types of cancers. They have been involved in various mechanisms, for instance, regulation of transcription, protein modification, and translation [6]. N6-methyladenosine (m6A)-related LncRNAs have been rarely studied in myeloid leukemia
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
